Video transcript:

Advances in treatment for cancer have greatly improved survivability when the cancer is caught early. However, despite global spending of over $100 billion annually on cancer diagnostics, over 50% of cancers are diagnosed at late stage where survivability plummets.

Imagion Biosystems is seeking to change that narrative by enabling earlier, more accurate cancer detection through molecular MRI. Recently, the company completed a $3.5 million capital raise to advance the clinical development of its MagSense® imaging agent platform.

This new class of targeted imaging agents works with the over 50,000 MRI scanners in use globally, adding molecular specificity to MRI’s high resolution. Having already completed a phase one study for the HER2 breast cancer product, the company now plans to file an IND with the USFDA with a goal of commencing the next phase of clinical investigation in early 2026.

Leading MRI physicists at Wayne State University are collaborating with Imagion to optimize imaging protocols and apply advanced quantitative imaging techniques, which will not only improve readability and image quality but also enable the development of AI tools for automated detection. Data from the clinical study will be used to train these AI models.

The capital raise will also enable the company to begin IND-enabling studies for its prostate and ovarian cancer imaging agents, which have already been validated in preclinical work.

Altogether, these three indications represent over $2 billion in addressable market opportunity. Imagion’s MagSense® molecular imaging technology has the potential to be a safer, more accurate way to non-invasively detect cancers.

We invite you to follow us on our journey towards changing the way we see cancer.